ACAD's Aroon Indicator triggered a bullish signal on June 16, 2022. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 218 similar instances where the Aroon Indicator showed a similar pattern. In 186 of the 218 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
The Momentum Indicator moved above the 0 level on June 14, 2022. You may want to consider a long position or call options on ACAD as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ACAD moved above its 50-day moving average on June 16, 2022 date and that indicates a change from a downward trend to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where ACAD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ACAD broke above its upper Bollinger Band on June 16, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.216) is normal, around the industry mean (24.469). P/E Ratio (0.000) is within average values for comparable stocks, (93.841). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.919). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (4.686) is also within normal values, averaging (306.529).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceuticals drugs for treatment of central nervous system disorders
|MFs / NAME||Price $||Chg $||Chg %|
|Cohen & Steers Global Infrastructure A|
|MFS Equity Income R2|
|Rockefeller Climate Solutions Instl|
|Franklin Mutual Quest R|
|American Funds Europacific Growth 529F2|
A.I.dvisor tells us that ACAD and NMTR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACAD and NMTR's prices will move in lockstep.
|NMTR - ACAD|
|ROIV - ACAD|
|ALLK - ACAD|
|EQRX - ACAD|
|GTBP - ACAD|